2026-10-28 11:01:57 UTC#528055newconfirmednews
MGNX stock news
MGNX stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.
See the full wire12 wire items
2026-10-26 16:44:00 UTC#516129updateconfirmednews
MacroGenics shares drop 10% as Phase 2 Linnet trial of lorigerlimab reports patient death and high adverse event rates
2026-10-26 11:27:21 UTC#514254newconfirmednews
MacroGenics reports 25% ORR for lorigerlimab in Phase 2 LINNET trial for clear cell gynecologic cancer
2026-09-16 19:16:07 UTC#323146newconfirmednews
MacroGenics advances Bizaxofusp to Phase III; MDNA11 data expected in Q4
2026-09-16 14:14:45 UTC#321293newconfirmednews
MacroGenics (MGNX) reports strengthened financials with cash runway extended through 2028
2026-08-17 16:48:00 UTC#185806newconfirmednews
B. Riley Securities raises MacroGenics (MGNX) price target to $11.00 from $9.00, maintains Buy
2026-08-13 20:13:34 UTC#174177updateconfirmednews
MacroGenics Q2 revenue miss driven by milestone timing; manufacturing sale boosts net income
reutersimportance 0.40trust 0.90MacroGenics, Inc. -0.20Sanofi +0.30Bora Pharmaceuticals Co., Ltd. +0.20+2 entities
2026-08-13 20:11:16 UTC#174126newconfirmednews
MacroGenics Q2 GAAP EPS -$1.10 misses by $1.02, Revenue $32.83M misses by $26.31M
2026-08-11 20:51:10 UTC#161258newconfirmednews
Gilead Sciences exercises option for MacroGenics preclinical bispecific program, triggering $10M payment
2026-08-10 11:00:22 UTC#152030newforecastnews
MacroGenics (MGNX) Q2 2026 Earnings Preview: Expected Revenue $59.14M, EPS Loss of $0.08
2026-07-24 15:27:41 UTC#75804newconfirmednews
MacroGenics shares decline following release of disappointing early-stage clinical trial data
2026-07-23 21:12:00 UTC#72001newconfirmednews